Brilacidin for OM looks compelling and I have taken a position for topline. Beyond that, a quick look at 10K's from 2012-17 show almost 50% dilution and very little pipeline progress for it. Kevetrin has essentially taken 5+ years to get move from IND to P2a. Prurisol hasn't progressed much better. Anyone care to address this red flag?
Disclosure: I was quite familiar with CTIX, in and out numerous times going back to 2012-15. Since then I have occasionally glanced at the ticker. Needless too say I have not been impressed with the progress here.